How CREXONT works - Crexont Site

how crexont works

In a clinical pharmacology study, CREXONT levodopa levels were compared with other forms of oral CD/LD

Laura,
on CREXONT since 2024

Main measurement

Levodopa levels of CREXONT compared with RYTARY® and IR CD/LD

CREXONT sustained for 4.8 hours (mean 587 mg LD)

RYTARY sustained for 4.8 hours (mean 538 mg LD)

IR CD/LD sustained for 1.9 hours (mean 168 mg LD)

In a different analysis of the same study, CREXONT levodopa levels outlasted RYTARY and IR CD/LD^*†

Uniquely designed capsule

In a clinical pharmacology study, CREXONT provided the longest-lasting oral levodopa levels^*†

Immediate-release granules

Dissolve quickly, allowing them to work within 1 hour

Immediate-release CD/LD granules

Extended-release pellets

Release levodopa slowly so levels last longer*

Extended-release LD pellets

Hover over the capsule to view contents

Capsule and contents shown for illustrative purposes only.

CREXONT is designed to gradually release levodopa in the part of the gut where it is best absorbed, although the exact site and duration of absorption is unknown

*In a clinical pharmacology study, the duration of levodopa levels was defined by how long the levels of CREXONT, RYTARY, and IR CD/LD were maintained in the blood above half the maximum concentration.

†This was a post hoc analysis of a secondary measure in the clinical pharmacology study; CREXONT vs RYTARY P=0.010; CREXONT vs IR CD/LD P<0.0001.

More “Good On” time

Explore the benefits of CREXONT

MAIN MEASUREMENT

30 mins more “Good On” time with less frequent dosing^‡§

compared with IR CD/LD

‡“Good On” time is defined as “On” time without troublesome dyskinesia. Change in “Good On” time was measured by comparing values at the end of study to baseline; P=0.019 vs IR CD/LD.

^§This was the average dose frequency during the double-blind maintenance period.

SECONDARY MEASUREMENT

30 mins less “Off” time per day^||¶

compared with IR CD/LD

^||This was a secondary endpoint of the study.

^¶Study end=Week 20 or early termination; P=0.025 vs IR CD/LD.

A DIFFERENT ANALYSIS OF THE SAME STUDY

>1 hr 30 mins more “Good On” time^# per dose^**

compared with IR CD/LD

^#“Good On” time is defined as “On” time without troublesome dyskinesia.

**This was a post hoc analysis of the study; P<0.0001 vs IR CD/LD.

MAIN MEASUREMENT

30 mins more “Good On” time with less frequent dosing^‡§

In a clinical study, people who took CREXONT an average of 3 times a day achieved 30 minutes more “Good On”
time per day than those taking IR CD/LD an average of 5 times a day

^‡“Good On” time is defined as “On” time without troublesome dyskinesia. Change in “Good On” time was measured by comparing values at the end of study to baseline; P=0.019 vs IR CD/LD.

^§This was the average dose frequency during the double-blind maintenance period.

In a clinical study, people who took CREXONT an average of 3 times a day achieved 30 minutes more “Good On” time per day than those taking IR CD/LD an average of 5 times a day

SECONDARY MEASUREMENT

30 mins less “Off” time per day^||¶

People who took CREXONT had 30 minutes less “Off” time per day compared with those who took IR CD/LD

^||This was a secondary endpoint of the study.

^¶Study end=Week 20 or early termination; P=0.0252 vs IR CD/LD.

People who took CREXONT had 30 minutes less “Off” time per day compared with those who took IR CD/LD

A DIFFERENT ANALYSIS OF THE SAME STUDY

>1 hr 30 mins more “Good On” time^# per dose^**

In a clinical study of a dose-to-dose comparison, people took CREXONT fewer times per day and experienced over  
an hour and a half more “Good On” time per dose than people taking IR CD/LD

^#“Good On” time is defined as “On” time without troublesome dyskinesia.

**This was a post hoc analysis of the study; P<0.0001 vs IR CD/LD.

In a clinical study of a dose-to-dose comparison, people took CREXONT fewer times per day and experienced over an hour and a half more “Good On” time per dose than people taking IR CD/LD

The most common side effects (incidence ≥3% and greater than IR CD/LD) were nausea and anxiety

In a clinical pharmacology study, CREXONT levodopa levels were compared with other forms of oral CD/LD

Levodopa levels of CREXONT compared with RYTARY® and IR CD/LD

In a clinical pharmacology study, CREXONT provided the longest-lasting oral levodopa levels^*†

Dissolve quickly, allowing them to work within 1 hour

Release levodopa slowly so levels last longer*

Explore the benefits of CREXONT

Explore the benefits of CREXONT

CREXONT offers personalized dosing

INDICATION

IMPORTANT SAFETY INFORMATION

INDICATION

IMPORTANT SAFETY INFORMATION

In a clinical pharmacology study, CREXONT levodopa levels were compared with other forms of oral CD/LD

Levodopa levels of CREXONT compared with RYTARY® and IR CD/LD

In a clinical pharmacology study, CREXONT provided the longest-lasting oral levodopa levels*†

Dissolve quickly, allowing them to work within 1 hour

Release levodopa slowly so levels last longer*

Explore the benefits of CREXONT

Explore the benefits of CREXONT

CREXONT offers personalized dosing

INDICATION

IMPORTANT SAFETY INFORMATION

Está a punto de abandonar nuestro sitio.

You are now leaving this site

In a clinical pharmacology study, CREXONT provided the longest-lasting oral levodopa levels^*†